OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 million. The deal comes as traditional IPOs have mostly ground to a halt due to uncertain market conditions, but Ligand is making a longer-term bet on growing demand for antibody drug discovery services.
Braeden Lichti, a Canadian investor and co-founder of a private investment firm has launched several healthcare companies, talks about how he got his start.
By Michael Schroeder Thursday, March 24, 2022 6:39 PM
The company is using the funding to grow its product development and research teams, and expand the clinical services offered by its nurse support team. The Series C round was led by D1 Capital Partners and two new investors: the Medtech Convergence Fund and an undisclosed strategic investor.
OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 million. The deal comes as traditional IPOs have mostly ground to a halt due to uncertain market conditions, but Ligand is making a longer-term bet on growing demand for antibody drug discovery services.
By Stephanie Baum Thursday, March 24, 2022 2:55 PM
A webinar, sponsored by Surescripts on April 28, will include: Surescripts CEO Tom Skelton, Epic CEO Judy Faulkner, Healthcare Leadership Council President Mary Grealy, McKesson Prescription Technology Solutions President Nathan Mott, and UC San Francisco Assistant Professor of Medicine A. Jay Holmgren. Register today!
Single-cell analysis biotech Celsius Therapeutics has raised $83 million to advance its pipeline of drugs for autoimmune disorders and cancer. The startup's lead autoimmune program, a TREM1-blocking antibody for inflammatory bowel disease, is expected to begin human testing in early 2023.
In this complex and rapidly changing claims denial environment, providers must take a proactive approach to stay ahead of the game. Here's what providers can do to successfully navigate the audit landscape.
EHR powerhouse Epic Systems sued Tata Consultancy Services in 2014 for stealing trade secrets and the court awarded Epic $940 million, which was reduced to $420 million in 2017 and again to $280 million in 2020. The Supreme Court this week rejected Epic's request to raise the amount back up to $420 million.
In this episode of the MedCity Pivot Podcast, Jonathan Bush talks about his latest venture - Zus Health - through which he wants to help digital health companies share data to create a universal patient off of which new products can be created to serve payers, providers and others with the ultimate goal of improving patient outcomes.
No comments